IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...

Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Verizon Innovative Learning, an award-winning education initiative, has reached ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...